European Commission vs Big Pharma, or profit vs access?
Drug Discovery World
MARCH 29, 2023
UMNs have been defined in the context of the draft as diseases where there’s a lack of good treatments, and which have a high burden 3. For rare disease drugs, a variable RDP period of five, nine, or ten years, depending on the novelty of the drug. appeared first on Drug Discovery World (DDW).
Let's personalize your content